Reviva Pharmaceuticals - CW23 | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.06.

EBIT: As of FY2025 Q3, the actual value is USD -4.086 M.

Net Loss

• The Company reported a net loss of approximately $4.0 million, or $0.06 per share, for the three months ended September 30, 2025, compared to a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024.

Cash and Cash Equivalents

• As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13.5 million as of December 31, 2024.

Operating Expenses

• Research and development expenses were $2,131,444 for the three months ended September 30, 2025, compared to $6,858,285 for the same period in 2024.
• General and administrative expenses were $1,898,397 for the three months ended September 30, 2025, compared to $1,604,249 for the same period in 2024.

Total Operating Expenses

• Total operating expenses amounted to $4,029,841 for the three months ended September 30, 2025, compared to $8,462,534 for the same period in 2024.

Loss from Operations

• Loss from operations was - $4,029,841 for the three months ended September 30, 2025, compared to - $8,462,534 for the same period in 2024.

Other Income (Expense)

• Total other income, net was $21,908 for the three months ended September 30, 2025, compared to $96,736 for the same period in 2024.

Outlook / Guidance

• Reviva Pharmaceuticals Holdings, Inc. plans a pre-NDA meeting with the FDA in Q4 2025 to discuss brilaroxazine’s path to approval for schizophrenia, with a potential NDA submission targeted for Q2 2026. The company is also pursuing partnership opportunities for the development of its pipeline.